Bedaquiline
Diarylquinoline Antimycobacterial — ANTIINFECTIVES FOR SYSTEMIC USE
Also known as: bedaquiline fumarate, sirturo, TMC207
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Bedaquiline is an onp drug in the Diarylquinoline Antimycobacterial class catalogued in DrugCentral. It was first approved by the FDA in 2012. DrugCentral lists 4 molecular targets, including atpE, KCNH2 and atpE. Recorded indications include Drug resistant tuberculosis and Pulmonary tuberculosis.
- Approval status: onp (first approved 2012 by the FDA).
- Drug class: Diarylquinoline Antimycobacterial.
- Molecular targets: atpE, KCNH2, atpE and atpE|atpD|atpA|atpG|atpC|atpFH|atpF|atpB (4 listed in DrugCentral).
- Indications: Drug resistant tuberculosis and Pulmonary tuberculosis.
- ATC code: J04AK05 (Other drugs for treatment of tuberculosis).
- Molecular formula: C32H31BrN2O2; molecular weight 555.52 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (2)
- Drug resistant tuberculosis
- Pulmonary tuberculosis
Mechanism & targets
| Established pharmacologic class | Diarylquinoline Antimycobacterial |
|---|
Molecular targets (4)
| Target | Gene | Action | Activity |
|---|---|---|---|
| ATP synthase subunit c | atpE | unknown | IC50 8.60 |
| Potassium voltage-gated channel subfamily H member 2 | KCNH2 | unknown | IC50 6.43 |
| ATP synthase subunit c | atpE | unknown | Kd 6.30 |
| ATP synthase | atpE|atpD|atpA|atpG|atpC|atpFH|atpF|atpB | inhibitor | — |
Regulatory approvals (2)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2018-01-19 | PMDA | — | Janssen Pharmaceutical KK | |
| 2012-12-28 | FDA | — | JANSSEN THERAP | Yes |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
J04AK05 | ANTIINFECTIVES FOR SYSTEMIC USE › ANTIMYCOBACTERIALS › DRUGS FOR TREATMENT OF TUBERCULOSIS › Other drugs for treatment of tuberculosis |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Electrocardiogram QT prolonged | 1827.0 |
| Neuropathy peripheral | 772.7 |
| Hepatotoxicity | 695.1 |
| Anaemia | 479.2 |
| Off label use | 243.2 |
| Optic neuritis | 236.2 |
| Drug resistance | 165.8 |
| Intentional product use issue | 161.1 |
| Cardiopulmonary failure | 126.0 |
| Drug-induced liver injury | 125.7 |
| Death | 120.6 |
| Aspartate aminotransferase increased | 113.7 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Bedaquiline is on its molecule page.
| Molecular formula | C32H31BrN2O2 |
|---|---|
| Molecular weight | 555.52 g/mol |
| CAS number | 843663-66-1 |
| InChIKey | QUIJNHUBAXPXFS-XLJNKUFUSA-N |
| PubChem CID | 5388906 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Bedaquiline used for?
DrugCentral lists the following indications for Bedaquiline: Drug resistant tuberculosis and Pulmonary tuberculosis.
How does Bedaquiline work?
Its molecular targets in DrugCentral include atpE, KCNH2, atpE and atpE|atpD|atpA|atpG|atpC|atpFH|atpF|atpB (inhibitor).
When was Bedaquiline first approved?
Bedaquiline was first approved by the FDA in 2012.
What drug class does Bedaquiline belong to?
Bedaquiline is in the Diarylquinoline Antimycobacterial class.
What is the chemical formula of Bedaquiline?
Bedaquiline has the molecular formula C32H31BrN2O2 and a molecular weight of 555.52 g/mol.
Browse: all drugs starting with B · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 4741 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL2105700 — compound record and bioactivity
- PubChem CID 5388906 — chemical identifiers
- DrugBank DB08903 — drug record
- FDA UNII 78846I289Y — substance identity
- DailyMed: FDA labels for Bedaquiline — current prescribing information (label search)
- UniProt Q12809 (KCNH2) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.